Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis


A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite 2′,2′-difluoro-deoxyuridine (dFdU) in patients 3 years of age and older with neoplastic meningitis. Gemcitabine was administered via Ommaya reservoir or lumbar puncture at… (More)
DOI: 10.1007/s00280-007-0601-x

6 Figures and Tables


  • Blog articles referencing this paper

  • Presentations referencing similar topics